A study by the Mildred Scheel Early Career Center group led by Dr. Mohamed Elgendy at the TUD Faculty of Medicine provides fundamental insights into cancer biology. Published in Nature Communications, ...

The researchers have succeeded in tracing two classic hallmarks of cancer – the evasion of apoptosis (a form of programmed cell death) and the ...

STOCKHOLM, Sweden, December 22, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has signed a non-binding letter of intent (LOI) with Novakand ...

STOCKHOLM, Sweden, December 22, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has signed a non-binding letter of intent (LOI) with Novakand ...

Karolinska Development AB ( ($SE:KDEV) ) has provided an update. Karolinska Development’s portfolio company SVF Vaccines has signed a non-binding ...

Data from a new mouse model may help advance therapeutic development in celiac disease, including improved TG2 inhibitors and ...

VV169 saw complete clearance of disseminated myeloma tumors within 28 daysAnother dataset highlights Vyriad’s work in improved vector retargeting strategies in a comparative study of three methods for ...

Triple-negative breast cancer (TNBC) is one of the hardest breast cancers to treat because it grows quickly, spreads early and often becomes resistant to therapy. In a new preclinical study, ...

Following peer-reviewed publication and independent expert review of findings, the LOI advances Lunai's tumor-regressing immune-cell platform toward scalable therapies for aggressive cancers ...